The GTSE1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HT29 human colorectal adenocarcinoma cell line. This heterogeneous pool ensures robust disruption of GTSE1 without the need for clonal isolation, maintaining genetic diversity that better mimics physiological tumor conditions. The polyclonal format is ideal for loss-of-function investigations into mitotic regulation, cell cycle control, and tumor biology.
HT29 cells are a well-established colorectal adenocarcinoma model featuring epithelial morphology and mutations in TP53 and APC, two critical tumor suppressors often inactivated in colorectal cancer. They are routinely employed to study intestinal epithelial biology, drug absorption, and oncogenic signaling pathways. Their consistent growth characteristics and defined genomic lesions make them an excellent chassis for CRISPR/Cas9-mediated gene knockout and functional genomic screens.
GTSE1 (G2 and S phase-expressed protein 1) is a downstream target of p53 that operates as a key mitotic regulator. It is transcriptionally upregulated by TP53 and FOXM1, and exerts its function by stabilizing spindle microtubules and facilitating chromosome congression. GTSE1 interacts physically with BUB1 and TPX2, linking the p53 pathway to the mitotic machinery. In the G2/M phase, GTSE1 acts upstream of Aurora A (AURKA), PLK1, Cyclin B1, and CDK1, ensuring timely mitotic entry and proper spindle assembly checkpoint function.
Within HT29 cells, which express mutant p53, knockout of GTSE1 results in severe mitotic spindle abnormalities, prolonged mitosis, and impaired cellular proliferation. These effects reveal p53-independent roles of GTSE1 in maintaining mitotic fidelity, making the model highly relevant for studying GTSE1-driven oncogenesis in colorectal cancer, where high GTSE1 levels correlate with poor clinical outcome.
This polyclonal knockout product supports a wide range of experimental approaches, including cell cycle analysis by flow cytometry, determination of mitotic index, and immunofluorescence staining for spindle markers such as ??-tubulin and pericentrin. Western blotting can assess levels of p53, cyclin B1, and other G2/M regulators. The cells are also suitable for proliferation assays (MTT, BrdU), transcriptome profiling via RNA-seq, and live-cell imaging to observe mitotic dynamics. Additionally, they serve as a platform for drug sensitivity testing and mechanistic studies of mitotic checkpoint control. For further details, please contact Ascent Research.
